Autopsy report · NCT03739801
MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Cause of deathStaffing, sites or logistics
“PI left”
Life of this trial
- Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.
Vital statistics
- Status
- Withdrawn
- Phase
- Phase 1, Phase 2
- Sponsor
- University of Southern California
- Sponsor type
- University, hospital or other
- Conditions
- Locally Advanced Unresectable Gastric Adenocarcinoma; Metastatic Gastroesophageal Junction Adenocarcinoma; Metastatic Unresectable Gastric Adenocarcinoma; Unresectable Gastroesophageal Junction Adenocarcinoma; Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma
- Interventions
- Liposomal Irinotecan; Quality-of-Life Assessment; Questionnaire Administration; Ramucirumab
- Participants
- 0
- Sites
- 1
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.